Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
Year: 2022
Type: article
Study design: Observational Study
Source: Blood
Authors: Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher J. Ferreri, Shebli Atrash, Jack Khouri, Peter M. Voorhees, Danai Dima, Gary Simmons, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, Sally Arai, David B. Miklos, Charlotte B Wagner, James Davis, Douglas W. Sborov, Taiga Nishihori, Melissa Alsina, Frederick L. Locke, Rebecca Gonzalez, M. Hakan Kocoglu, Aishwarya Sannareddy, Aimaz Afrough, Joseph P. McGuirk, Leyla O. Shune, Krina Patel, Doris K. Hansen
Institutions: Stanford Medicine, Stanford University, Moffitt Cancer Center, Medical University of South Carolina, The University of Texas MD Anderson Cancer Center, Levine Cancer Institute, Cleveland Clinic, VCU Massey Comprehensive Cancer Center, Huntsman Cancer Institute, University of Utah, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, University of Kansas Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310163436